US2021140972A1PendingUtilityA1
Mechanism of action
Est. expiryJun 18, 2035(~8.9 yrs left)· nominal 20-yr term from priority
Inventors:James Philip O'ConnellJohn Robert PorterAlastair David Griffiths LawsonBoris KroeplienStephen Edward RapeckiTimothy John NormanDavid James McmillanGraham John WarrellowDaniel Christopher BrookingsRikki Peter Alexander
G01N 2500/04G01N 2333/7151G01N 2333/525G01N 33/6863C07K 2317/92C07K 2317/565C07K 2317/34C07K 2317/32C07D 471/04C07D 401/14C07D 401/04A61P 35/00G01N 33/6845C07K 2317/24C07K 2317/55C07K 14/70575C07K 14/525C07K 16/241A61K 47/6425C07D 471/00G01N 2500/02A61P 37/00C07D 235/04C07D 239/26C07D 213/72G01N 33/6854
77
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.
Claims
exact text as granted — not AI-modified1 - 20 . (canceled)
21 . A compound of formula (5), or a pharmaceutically acceptable salt or solvate thereof:
22 . A complex comprising a trimeric protein that is a tumor necrosis factor (TNF) superfamily member and the compound of claim 21 .
23 . (canceled)
24 . A method of treating and/or preventing a disorder selected from an autoimmune, an inflammatory, a neurological, a neurodegenerative, a pain, a nociceptive, and a cardiovascular disorders in a subject in need thereof, comprising administering the compound of claim 21 to the subject.
25 . The method of claim 24 , wherein rheumatoid arthritis, Crohn's disease, psoriasis, systemic lupus erythematosus, Alzheimer's disease, Parkinson's disease or epilepsy is treated and/or prevented.
26 . A pharmaceutical composition comprising the compound of claim 21 and a pharmaceutically acceptable carrier.
27 . A method of treating and/or preventing a disorder selected from an autoimmune, an inflammatory, a neurological, a neurodegenerative, a pain, a nociceptive, and a cardiovascular disorder in a subject in need thereof, comprising administering the complex of claim 22 to the subject.
28 . A pharmaceutical composition comprising the complex of claim 22 and a pharmaceutically acceptable carrier.
29 . The method of claim 27 , wherein rheumatoid arthritis, Crohn's disease, psoriasis, systemic lupus erythematosus, Alzheimer's disease, Parkinson's disease or epilepsy is treated and/or prevented.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.